Literature DB >> 12622777

TNFA-TNFB haplotypes modify susceptibility to type I diabetes mellitus independently of HLA class II in a Moroccan population.

L Bouqbis1, O Akhayat, H-J Garchon, F Calafell, H Izaabel.   

Abstract

The contribution of single nucleotide polymorphisms in tumor necrosis factors (TNF) alpha and beta to autoimmune diseases, and to type 1 diabetes mellitus (T1DM) in particular, is not well established, and may be confounded by linkage disequilibrium to class II HLA genes. At least two polymorphisms seem to have functional relevance in the respective genes: TNFA-307 and TNFB+252. We have typed these two polymporphisms in samples of Moroccan T1DM patients and controls for which class II HLA genes had already been typed. Tumor necrosis factors and compound TNF-class II HLA haplotypes were inferred; it was the first time that such a design had been implemented. Independent of linkage disequilibrium with class II HLA, TNF haplotype TNFA-307*2 - TNFB+252*2 showed a significant protective effect (OR = 0.031), partly exacerbated by partial linkage to protective class II haplotypes. Such effect could be detected because Morocco shows the highest frequency of the TNFA-307*2 allele yet reported. This highlights the possible population differences in alleles contributing to autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12622777     DOI: 10.1034/j.1399-0039.2003.610106.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  7 in total

1.  Linkage disequilibrium with predisposing DR3 haplotypes accounts for apparent effects of tumor necrosis factor and lymphotoxin-alpha polymorphisms on type 1 diabetes susceptibility.

Authors:  Janelle A Noble; Ana M Valdes; Julie A Lane; Amy E Green; Henry A Erlich
Journal:  Hum Immunol       Date:  2006-10-30       Impact factor: 2.850

2.  Distinct roles for lymphotoxin-alpha and tumor necrosis factor in the control of Leishmania donovani infection.

Authors:  Christian R Engwerda; Manabu Ato; Simona Stäger; Clare E Alexander; Amanda C Stanley; Paul M Kaye
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

3.  Modulation of type 1 diabetes susceptibility by tumor necrosis factor alpha -308 G/A and lymphotoxin alpha +249 A/G haplotypes and lack of linkage disequilibrium with predisposing DQB1-DRB1 haplotypes in Bahraini patients.

Authors:  Mouna Stayoussef; Fayza A Al-Jenaidi; Abduljabbar Al-Abbasi; Khadija Al-Ola; Haya Khayyat; Touhami Mahjoub; Wassim Y Almawi
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

4.  Associations between TNF gene polymorphisms (-308 A/G, -238 A/G, -1031 C/T and -857 T/C) and genetic susceptibility to T1D: a meta-analysis.

Authors:  Peng-Fei Wen; Xiao-Song Wang; Min Zhang; Han Cen; Hai-Feng Pan; Qian-Ling Ye; Chen Mao; Dong-Qing Ye
Journal:  Endocrine       Date:  2014-02-11       Impact factor: 3.633

5.  Family-based analysis of tumor necrosis factor and lymphotoxin-alpha tag polymorphisms with type 1 diabetes in the population of South Croatia.

Authors:  Vesna Boraska; Eleftheria Zeggini; Christopher J Groves; Nigel W Rayner; Veselin Skrabić; Mahamadou Diakite; Kirk A Rockett; Dominic Kwiatkowski; Mark I McCarthy; Tatijana Zemunik
Journal:  Hum Immunol       Date:  2009-01-22       Impact factor: 2.850

6.  Is the association between TNF-alpha-308 A allele and DMT1 independent of HLA-DRB1, DQB1 alleles?

Authors:  Grazyna Deja; Przemysława Jarosz-Chobot; Joanna Polańska; Urszula Siekiera; Ewa Małecka-Tendera
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

7.  A study of the TNF/LTA/LTB locus and susceptibility to severe malaria in highland papuan children and adults.

Authors:  Louise M Randall; Enny Kenangalem; Daniel A Lampah; Emiliana Tjitra; Esther D Mwaikambo; Tjandra Handojo; Kim A Piera; Zhen Z Zhao; Fabian de Labastida Rivera; Yonghong Zhou; Karli M McSweeney; Lien Le; Fiona H Amante; Ashraful Haque; Amanda C Stanley; Tonia Woodberry; Ervi Salwati; Donald L Granger; Maurine R Hobbs; Ric N Price; J Brice Weinberg; Grant W Montgomery; Nicholas M Anstey; Christian R Engwerda
Journal:  Malar J       Date:  2010-10-29       Impact factor: 2.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.